Abstract
Achromatopsia (ACHM) is caused by a progressive loss of cone photoreceptors leading to color blindness and poor visual acuity. Animal studies and human clinical trials have shown that gene replacement therapy with adeno-associate virus (AAV) is a viable treatment option for this disease. Although there have been successful attempts to optimize capsid proteins for increased specificity, it is simpler to restrict expression via the use of cell type-specific promoters. To target cone photoreceptors, a chimeric promoter consisting of an enhancer element of interphotoreceptor retinoid-binding protein promoter and a minimal sequence of the human transducin alpha-subunit promoter (IRBPe/GNAT2) was created. Additionally, a synthetic transducin alpha-subunit promoter (synGNAT2/GNAT2) containing conserved sequence blocks located downstream of the transcriptional start was created. The strength and specificity of these promoters were evaluated in murine retina by immunohistochemistry. The results showed that the chimeric, (IRBPe/GNAT2) promoter is more efficient and specific than the synthetic, synGNAT2/GNAT2 promoter. Additionally, IRBPe/GNAT2-mediated expression was found in all cone subtypes and it was improved over existing promoters currently used for gene therapy of achromatopsia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carvalho LS, Xu J, Pearson RA, Smith AJ, Bainbridge JW, Morris LM et al (2011) Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 20(16):3161–3175
Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL et al (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20(9):999–1004
Michalakis S, Muhlfriedel R, Tanimoto N, Krishnamoorthy V, Koch S, Fischer MD et al (2010) Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 18(12):2057–2063
Michalakis S, Muhlfriedel R, Tanimoto N, Krishnamoorthy V, Koch S, Fischer MD et al (2012) Gene therapy restores missing cone-mediated vision in the CNGA3-/- mouse model of achromatopsia. Adv Exp Med Biol 723:183–189
Pang JJ, Deng WT, Dai X, Lei B, Everhart D, Umino Y et al (2012) AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS.One 7(4):e35250
Mancuso K, Hauswirth WW, Li Q, Connor TB, Kuchenbecker JA, Mauck MC et al (2009) Gene therapy for red-green colour blindness in adult primates. Nature 461(7265):784–787
Alexander JJ, Umino Y, Everhart D, Chang B, Min SH, Li Q et al (2007) Restoration of cone vision in a mouse model of achromatopsia. Nat Med 13(6):685–687
Komaromy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A et al (2010) Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 19(13):2581–2593
Thiadens AA, Somervuo V, van den Born LI, Roosing S, van Schooneveld MJ, Kuijpers RW et al (2010) Progressive loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 51(11):5952–5957
Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21(4):583–593
Glushakova LG, Timmers AM, Pang J, Teusner JT, Hauswirth WW (2006) Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors. Invest Ophthalmol Vis Sci 47(8):3505–3513
Komaromy AM, Alexander JJ, Cooper AE, Chiodo VA, Glushakova LG, Acland GM et al (2008) Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. Gene Ther 15(14):1049–1055
Li A, Zhu X Craft CM (2002) Retinoic acid upregulates cone arrestin expression in retinoblastoma cells through a Cis element in the distal promoter region. Invest Ophthalmol Vis Sci 43(5):1375–1383
Jacobson SG, Acland GM, Aguirre GD, Aleman TS, Schwartz SB, Cideciyan AV et al (2006) Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 13(6):1074–1084
Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr et al (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28(2):158–167
Daniele LL, Lillo C, Lyubarsky AL, Nikonov SS, Philp N, Mears AJ et al (2005) Cone-like morphological, molecular, and electrophysiological features of the photoreceptors of the Nrl knockout mouse. Invest Ophthalmol Vis Sci 46(6):2156–2167
Nikonov SS, Daniele LL, Zhu X, Craft CM, Swaroop A, Pugh EN Jr(2005) Photoreceptors of Nrl -/- mice coexpress functional S- and M-cone opsins having distinct inactivation mechanisms. J Gen Physiol 125(3):287–304
Ying S, Fong SL, Fong WB, Kao CW, Converse RL, Kao WW (1998) A CAT reporter construct containing 277 bp GNAT2 promoter and 214 bp IRBP enhancer is specifically expressed by cone photoreceptor cells in transgenic mice. Curr Eye Res 17(8):777–782
Ying S, Jansen HT, Lehman MN, Fong SL, Kao WW (2000) Retinal degeneration in cone photoreceptor cell-ablated transgenic mice. Mol Vis 6:101–108
Fong SL, Criswell MH, Belecky-Adams T, Fong WB, McClintick JN, Kao WW et al (2005) Characterization of a transgenic mouse line lacking photoreceptor development within the ventral retina. Exp Eye Res 81(4):376–388
Acknowledgment
The authors thank Seok-Hong Min, James Peterson, and Jingfen Sun for their excellent technical assistance. They also acknowledge grants from the Foundation Fighting Blindness, Research to Prevent Blindness, Inc. for partial support of this work.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, LLC
About this paper
Cite this paper
Dyka, F., Boye, S., Ryals, R., Chiodo, V., Boye, S., Hauswirth, W. (2014). Cone Specific Promoter for Use in Gene Therapy of Retinal Degenerative Diseases. In: Ash, J., Grimm, C., Hollyfield, J., Anderson, R., LaVail, M., Bowes Rickman, C. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 801. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3209-8_87
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3209-8_87
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3208-1
Online ISBN: 978-1-4614-3209-8
eBook Packages: MedicineMedicine (R0)